Inspire Veterinary Partners (IVPR)
OTHER OTC:IVPR
Top Page
Inspire Veterinary Partners
(OTC:IVPR)
Select Model
Select Model
Rating:38Underperform
Price Target:
$0.03
▼(-20.00% Downside)
Action:ReiteratedDate:01/22/26
The score is driven primarily by weak financial performance (negative profitability, high leverage, and negative operating/free cash flow) and bearish technical signals (below major moving averages with negative MACD). Additional downside risk comes from Nasdaq delisting and OTCQB move, while valuation is difficult to support due to a negative P/E and no dividend yield data.
Positive Factors
Strategic Growth Initiatives
The consulting agreement with 622 Capital LLC aims to enhance financial positioning and strategic growth, supporting long-term business development.
Negative Factors
High Leverage
High leverage can increase financial risk and limit flexibility, potentially impacting long-term financial stability and growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Growth Initiatives
The consulting agreement with 622 Capital LLC aims to enhance financial positioning and strategic growth, supporting long-term business development.
Read all positive factors
Inspire Veterinary Partners (IVPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$146.37K
Dividend YieldN/A
Average Volume (3M)44.35M
Price to Earnings (P/E)―
Beta (1Y)2.31
Revenue Growth-8.76%
EPS Growth99.64%
CountryUS
Employees113
SectorConsumer Cyclical
Sector Strength84
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)-0.41
Shares Outstanding118,953,260
10 Day Avg. Volume132,839,515
30 Day Avg. Volume44,350,689
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)17.02
Price to Sales (P/S)1.60
P/FCF Ratio-2.60
Enterprise Value/Market Cap93.95
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit2.90
Enterprise Value/Ebitda-1.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Inspire Veterinary Partners Business Overview & Revenue Model
Company Description
Inspire Veterinary Partners, Inc. owns and operates veterinary hospitals in the United States. The company specializes in small animal general practice hospitals, which serve companion pets, canine, and feline breeds, including equine care. It als...
How the Company Makes Money
Inspire Veterinary Partners generates revenue primarily through a combination of service fees from partnered veterinary practices and a percentage of the profits from these practices. The company charges management fees for its operational support...
Inspire Veterinary Partners Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
25
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.56M | 16.59M | 16.68M | 9.83M | 2.55M | 0.00 |
| Gross Profit | 4.73M | 3.29M | 3.55M | 2.55M | 829.29K | 0.00 |
| EBITDA | -8.36M | -9.50M | -10.84M | -2.91M | -977.46K | 0.00 |
| Net Income | -11.94M | -14.26M | -14.79M | -4.91M | -1.33M | -5.52K |
Balance Sheet | ||||||
| Total Assets | 23.96M | 20.20M | 21.79M | 20.19M | 6.33M | 21.97K |
| Cash, Cash Equivalents and Short-Term Investments | 341.75K | 523.69K | 178.96K | 444.25K | 2.06M | 21.97K |
| Total Debt | 13.94M | 16.37M | 18.42M | 23.61M | 6.69M | 0.00 |
| Total Liabilities | 19.79M | 18.63M | 22.58M | 25.32M | 7.20M | 0.00 |
| Stockholders Equity | 4.17M | 1.56M | -788.26K | -5.14M | -869.09K | 21.97K |
Cash Flow | ||||||
| Free Cash Flow | -4.34M | -10.24M | -4.20M | -2.84M | -2.32M | -5.52K |
| Operating Cash Flow | -4.23M | -10.01M | -3.82M | -2.66M | -1.01M | -5.52K |
| Investing Cash Flow | -1.96M | -237.98K | -1.87M | -14.67M | -4.02M | 0.00 |
| Financing Cash Flow | 5.89M | 10.59M | 5.63M | 15.71M | 7.07M | 269.16K |
Inspire Veterinary Partners Technical Analysis
Negative
0.04
Price Trends
0.16
Negative
0.54
Negative
0.92
Negative
Market Momentum
-0.04
Negative
32.78
Neutral
11.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVPR, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.16, and below the 200-day MA of 0.92, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 32.78 is Neutral, neither overbought nor oversold. The STOCH value of 11.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVPR.
Inspire Veterinary Partners Risk Analysis
Inspire Veterinary Partners disclosed 48 risk factors in its most recent earnings report. Inspire Veterinary Partners reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inspire Veterinary Partners Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
58 Neutral | $8.69M | -0.60 | 48.22% | ― | 13.71% | ― | |
40 Underperform | $6.92M | -1.97 | 357.74% | ― | -12.74% | 13.22% | |
38 Underperform | $146.37K | -0.59 | -331.80% | ― | -8.76% | 99.64% | |
| ― | $8.05M | -0.82 | -1.53% | ― | -2.53% | 99.45% |
* Consumer Cyclical Sector Average
IVPR
Inspire Veterinary Partners
0.01
-1.70
-99.42%
XWEL
XWELL
1.11
0.09
8.82%
MRM
MEDIROM Healthcare Technologies
1.10
0.73
197.30%
EJH
E-Home Household Service Holdings
0.10
-58.40
-99.83%
Inspire Veterinary Partners Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Inspire Veterinary Partners Begins Trading on OTCQB Market
Negative
Jan 21, 2026
On November 13, 2025, Inspire Veterinary Partners received notice from Nasdaq that the company’s Class A common stock had failed to meet the minimum bid price requirement for the prior 30 consecutive business days, triggering a potential sus...
Business Operations and StrategyPrivate Placements and Financing
Inspire Veterinary Executes Debt-for-Equity Financing Agreement
Neutral
Jan 20, 2026
On January 14, 2026, Inspire Veterinary Partners, Inc. entered into a Cancellation and Exchange Agreement with Target Capital 1 LLC, under which the company canceled $25,000 of principal outstanding on a June 10, 2025 promissory note in exchange f...
Business Operations and StrategyRegulatory Filings and Compliance
Inspire Veterinary Partners Expands Authorized Class A Share Count
Neutral
Jan 13, 2026
On January 9, 2026, Inspire Veterinary Partners, Inc. filed a Certificate of Amendment in Nevada to significantly increase its authorized Class A common stock from 100 million to 700 million shares, while leaving authorized Class B common stock an...
Executive/Board ChangesPrivate Placements and Financing
Inspire Veterinary Partners Announces New Convertible Note Financing
Neutral
Jan 12, 2026
On January 6, 2026, effective as of December 31, 2025, Inspire Veterinary Partners, Inc. entered into a securities purchase agreement with Manetto Hill Fund Series I LLC under which it may issue up to $1.626 million in convertible promissory notes...
Business Operations and StrategyPrivate Placements and Financing
Inspire Veterinary Partners Executes Debt-for-Equity Exchange Agreement
Neutral
Dec 30, 2025
On December 18, 2025, Inspire Veterinary Partners, Inc. entered into a Cancellation and Exchange Agreement with Target Capital 1 LLC under which the company agreed to cancel $150,000 of principal outstanding under a June 10, 2025 promissory note i...
Business Operations and StrategyPrivate Placements and Financing
Inspire Veterinary Partners Signs Consulting Agreement for Growth
Neutral
Dec 17, 2025
On December 12, 2025, Inspire Veterinary Partners, Inc. entered a Consulting Agreement with 622 Capital LLC to receive business development services aimed at business financing opportunities. As part of this agreement, the company will issue an ag...
Business Operations and StrategyShareholder Meetings
Inspire Veterinary Partners Holds Annual Stockholders Meeting
Neutral
Dec 11, 2025
On December 10, 2025, Inspire Veterinary Partners, Inc. held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and financial oversight. The stockholders elected directors to the board for te...
Delistings and Listing ChangesPrivate Placements and Financing
Inspire Veterinary Partners Amends Promissory Notes and Stock Terms
Neutral
Dec 5, 2025
Inspire Veterinary Partners, Inc. announced on December 1, 2025, a reduction in the Floor Price of its Series B Convertible Preferred Stock from $0.1879 to $0.05 per share, following agreements with accredited investors. Additionally, the company ...
Delistings and Listing ChangesRegulatory Filings and Compliance
Inspire Veterinary Faces Nasdaq Delisting Threat
Negative
Nov 24, 2025
Inspire Veterinary Partners, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, threatening suspension and delisting of its securities. The company has requested a hearing, scheduled for Januar...
Delistings and Listing ChangesRegulatory Filings and Compliance
Inspire Veterinary Faces Nasdaq Delisting Notice
Negative
Nov 17, 2025
On November 13, 2025, Inspire Veterinary Partners, Inc. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement due to its stock’s performance over the past 30 days. As a result, the company’s sec...
Business Operations and StrategyPrivate Placements and Financing
Inspire Veterinary Partners Issues Convertible Notes for Capital
Neutral
Nov 10, 2025
On November 5, 2025, Inspire Veterinary Partners, Inc. issued Senior Convertible Promissory Notes to Keystone Capital Partners, LLC and Seven Knots, LLC, each with a principal amount of $178,571.43. The notes, which mature on August 5, 2026, inclu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.